Bio-Techne (TECH) just put investors on notice with a conditional quarterly dividend of $0.08 per share, tied directly to its ...

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, ...

Germany’s Merck KGaA has announced a major acquisition agreement to buy U.S.-based life sciences company Bio-Techne Corp (NASDAQ:TECH) in a deal valued at approximately $11.3 billion, marking one of ...

Bio-Techne stock traded at EUR 64.94 on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4, 2026. The company operates ...

Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November ...

Bio-Techne (ISIN US09073M1045) has its next quarterly reporting date scheduled for November 4, 2026, according to MarketBeat.

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the ...